685 related articles for article (PubMed ID: 34745388)
1. Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer.
Zhao Z; Yang YB; Li XY; Li XG; Chu XD; Lin ZB; Zhang YR; Guo YG; Ding H; Pan YL; Wang L; Pan JH
Dis Markers; 2021; 2021():8686307. PubMed ID: 34745388
[TBL] [Abstract][Full Text] [Related]
2. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
[TBL] [Abstract][Full Text] [Related]
3. Construction of an N6-methyladenosine lncRNA- and immune cell infiltration-related prognostic model in colorectal cancer.
Yu ZL; Zhu ZM
Protoplasma; 2022 Jul; 259(4):1029-1045. PubMed ID: 34734333
[TBL] [Abstract][Full Text] [Related]
4. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer.
Liu Y; Wang T; Fang Z; Kong J; Liu J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871
[TBL] [Abstract][Full Text] [Related]
5. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients.
Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C
BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697
[TBL] [Abstract][Full Text] [Related]
6. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
[No Abstract] [Full Text] [Related]
7. Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma.
Qiu Y; Wang X; Fan Z; Zhan S; Jiang X; Huang J
Immun Inflamm Dis; 2021 Dec; 9(4):1596-1612. PubMed ID: 34432955
[TBL] [Abstract][Full Text] [Related]
8. lncRNAs AC156455.1 and AC104532.2 as Biomarkers for Diagnosis and Prognosis in Colorectal Cancer.
Kuang F; Luo D; Zhou M; Du J; Yang J
Dis Markers; 2022; 2022():4872001. PubMed ID: 36277972
[TBL] [Abstract][Full Text] [Related]
9. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma.
Yu ZL; Zhu ZM
Bioengineered; 2021 Dec; 12(1):1708-1724. PubMed ID: 33955330
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
Song Y; Qu H
BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
[TBL] [Abstract][Full Text] [Related]
12. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
13. Cross-Talk Between m
Song W; Ren J; Xiang R; Yuan W; Fu T
Front Immunol; 2022; 13():740960. PubMed ID: 35350786
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
Front Immunol; 2022; 13():951455. PubMed ID: 36189298
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel m6A-related lncRNA pair signature for predicting the prognosis of gastric cancer patients.
Wang JM; Li X; Yang P; Geng WB; Wang XY
BMC Gastroenterol; 2022 Feb; 22(1):76. PubMed ID: 35189810
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
[TBL] [Abstract][Full Text] [Related]
17. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma.
Wu Z; Zhang X; Chen D; Li Z; Wu X; Wang J; Deng Y
Front Immunol; 2021; 12():806189. PubMed ID: 35095893
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
19. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
Hu Y; Chen Y
Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
[TBL] [Abstract][Full Text] [Related]
20. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
